Navigation Links
OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
Date:3/24/2008

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML). The results of their study will be published the week of March 24th in the Proceedings of the National Academy of Sciences.

Gleevec, the targeted therapy identified by OHSU Cancer Institute Director Brian Druker, M.D., is the current first line therapy for CML. Gleevec works by inhibiting the activity of Bcr-Abl, an enzyme that is present only in CML cells and upon which these cells depend for survival. Although most patients with CML respond dramatically to Gleevec, some patients develop resistance to the drug. Most Gleevec-resistant CML cells carry a mutated form of Bcr-Abl, which prevents Gleevec from functioning properly. The second-generation drugs Sprycel and Tasigna have been developed as largely successful treatments for Gleevec-resistant patients. However, one mutated form of Bcr-Abl, called T315I, is resistant to all three clinical CML drugs and is a frequent cause of relapse.

Michael Deininger, M.D., Ph.D., head of the Hematologic Malignancies Section, and his research team in the OHSU Cancer Institute have shown that SGX393, developed by SGX Pharmaceuticals, Inc., San Diego, Calif., inhibits the T315I mutant and most, but not all, other Gleevec-resistant mutants. This was shown to be true using laboratory models as well as leukemia cells from patients with CML.

Researchers then took this success a step further. Using a method developed in their laboratory to rapidly and accurately forecast drug-resistant Bcr-Abl mutations, Deininger and colleagues established a resistance profile for SGX393. Though SGX393 showed a handful of mutation weak spots, the T315I mutation was absent among thousands of samples surveyed in the laboratory. In contrast, T315I was frequently recovered when running the screen with any of the other drugs.<
'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
(Date:6/1/2015)... "This milestone opens the doors to institutional ... to buy and sell shares of our Company. ... make recommendations to clients as they so choose. It ... shares of our Company,” said Kris Finstad, Content Checked’s ... OTCQB provides our investors greater confidence in the information ...
(Date:6/1/2015)... York, NY (PRWEB) June 01, 2015 ... by patients requesting celebrity features. Much like one would ... favorite stars’ noses, eyes, cheeks, chin and more to ... photo filtering apps like FaceTune are ushering in a ... Top Manhattan facial plastic surgeon, Sam Rizk, MD, FACS ...
(Date:6/1/2015)... June 1, 2015 – Atlanta, GA ... the areas of hospital medicine, emergency medicine, and pediatric ... expanded upon its partnership with AgileMD to provide the ... in a mobile application format available on iPhones, ... are very excited about the June 1 launch of ...
(Date:6/1/2015)... InstantLabs will co-develop and commercialize a ... a Cooperative Research and Development Agreement (CRADA) with the ... with U.S. Farm Bill legislation, only members of the ... the United States. , InstantLabs’ DNA-based technology will ... need rather than requiring samples be sent to centralized ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4
... Human papillomavirus infection linked to better prognosis, research suggests ... the human papillomavirus (HPV) may improve survival in patients ... They said the finding may explain why black Americans, ... poorer head and neck cancer survival rates. , "There ...
... , , Association,s Anti-Fraud ... Fraud, and Abuse in Medicare , , ... strongly supports the recent Medicare Fraud Strike Force crackdown on Medicare ... takes vital resources away from seniors and patients. Reducing fraud and ...
... , YOUNTVILLE, Calif., July 30 The following is being ... WHAT: A special hearing of the California Senate Veterans Affairs Committee at the ... was originally , scheduled for Friday, July 31, 2009 at 9 a.m.. , ... , ...
... , , DETROIT, July 30 ... Rev. Dr. Wendell Anthony: , , Congressman Thaddeus ... to apologize for his remarks to the Cambridge Police Department. ... he should start by issuing an apology to the citizens of ...
... PASADENA, Calif., July 30 AutoImmune Inc. (OTC ... Corp., and Eli Lilly and Company reported that dirucotide ... progression, as measured by the Expanded Disability Status Scale ... with secondary progressive multiple sclerosis (SPMS). In addition, there ...
... PLEASANTON, Calif., July 30 Thoratec Corporation (Nasdaq: THOR ... save, support and restore failing hearts, today announced that it will ... months of fiscal 2009 on Wednesday, August 5. , , ... its financial results and operating activities open to all interested parties ...
Cached Medicine News:Health News:Virus May Affect Survival in Head and Neck Cancer 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 3Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 4Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:Thoratec Schedules Second Quarter Conference Call, Webcast 2
(Date:6/1/2015)... -- Boston Biomedical, an industry leader in the development of ... pathways, will present clinical data today on the investigational ... the 2015 American Society of Clinical Oncology (ASCO) annual ... Data presented at ASCO highlight the potential of BBI608 ... to inhibition of the critical genes for maintaining cancer ...
(Date:6/1/2015)... /CNW Telbec/ -  Ergoresearch Ltd (TSXV: ERG) – based ... « Équilibre, orthèses et biomécanique» banner  – announces its ... All dollar amounts in the present release are in Canadian ... fiscal year 2015 ended this past March 31, 2015 totaled ... for the quarter ended March 31, 2014. This decrease can ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" ... ) is pleased to announce today that the ... the over-allotment option to purchase 1,000,550 common shares ... C$3.05 per Share granted to the Underwriters in ... which closed on April 30, 2015.  The Company ...
Breaking Medicine Technology:Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option 2
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
... Feb. 28, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... Appeal of the European Patent Office (EPO) has cancelled its ... decision upholding PDL,s  European Patent No. 0 451 216B (the ... the termination of the opposition appeal proceeding is that the ...
Cached Medicine Technology:S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final 2
Inquire...
... System consists of a sterile Hemostatic ... Compression System.,Both devices work together to ... achieves topical hemostasis by facilitating clotting ... Femoral Compression System provides external compression ...
... PRAXIS is an Electronic Medical Record system. ... EKG's, Vital Statistics, Medications, and everything you would ... charts cost you money. Someone has to write ... them, and organize them. Paper Charts get lost. ...
... Bausch & Lomb's Orbscan IIz is ... elevates diagnostics beyond mere topography. Unlike current ... the eye at standard points, the Orbscan ... 1.5 seconds to meticulously map the entire ...
Medicine Products: